Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | SRC | P12931 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2014380 | 0.90 | PTGS2 (0.50) | HPGDCYP2C19ALDH1A1SMN1; SMN2 | |
| SCHEMBL28615005 | 0.86 | EPHX1 (0.54) | HPGDTSHRALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL2016945 | 0.85 | CYP2C19 (0.52) | HPGDCYP2C19TSHRALDH1A1KMT2A | |
| SCHEMBL25225149 | 0.84 | L3MBTL1 (0.41) | HPGDALDH1A1POLBLMNA | |
| SCHEMBL30387929 | 0.84 | L3MBTL1 (0.41) | HPGDALDH1A1POLBLMNA | |
| SCHEMBL3360528 | 0.84 | POLB (0.51) | CYP2C19KMT2ACYP2D6POLBLMNA | |
| SCHEMBL29453509 | 0.84 | ACP3 (0.46) | HPGDCYP2C19TSHRALDH1A1KMT2A | |
| SCHEMBL28498531 | 0.83 | MMP8 (0.49) | HPGDKMT2ASMN1; SMN2CHRM1POLB | |
| SCHEMBL29085518 | 0.82 | KDM4E (0.48) | HPGDCYP2C19ALDH1A1SMN1; SMN2CYP2D6 | |
| SCHEMBL30371912 | 0.82 | CYP2C19 (0.61) | CYP2C19ALDH1A1SMN1; SMN2CYP2D6SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3214086-B1 | SUBSTITUTED DIHYDROPYRROLOPYRAZOLE COMPOUND | UBE INDUSTRIES (JP) | 2021-09-22 | — | — | EP | disclosed |
| EP-3214086-B1 | SUBSTITUTED DIHYDROPYRROLOPYRAZOLE COMPOUND | UBE INDUSTRIES (JP) | 2021-09-22 | — | — | EP | disclosed |
| US-10968238-B2 | Substituted dihydropyrrolopyrazole compound | UBE INDUSTRIES, LTD. (JP) | 2021-04-06 | — | — | US | disclosed |
| US-10968238-B2 | Substituted dihydropyrrolopyrazole compound | UBE INDUSTRIES, LTD. (JP) | 2021-04-06 | — | — | US | disclosed |
| CN-107074887-B | Substituted dihydropyrrolopyrazoles | 宇部兴产株式会社 | 2020-12-22 | — | — | CN | disclosed |
| US-10246426-B2 | Triazole compounds as T-type calcium channel blockers | IDORSIA PHARMACEUTICALS LTD (CH) | 2019-04-02 | — | — | US | disclosed |
| US-10131679-B2 | Substituted dihydropyrrolopyrazole compound | UBE INDUSTRIES, LTD. (JP) | 2018-11-20 | — | — | US | disclosed |
| WO-2017188358-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OR PREVENTION OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE | 宇部興産株式会社 | 2017-11-02 | — | — | WO | disclosed |
| US-20170313727-A1 | SUBSTITUTED DIHYDROPYRROLOPYRAZOLE COMPOUND | UBE INDUSTRIES, LTD. (JP) | 2017-11-02 | — | — | US | disclosed |
| US-20170313727-A1 | SUBSTITUTED DIHYDROPYRROLOPYRAZOLE COMPOUND | UBE INDUSTRIES, LTD. (JP) | 2017-11-02 | — | — | US | disclosed |
| WO-2017188369-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OR PREVENTION OF ATOPIC DERMATITIS | 宇部興産株式会社 | 2017-11-02 | — | — | WO | disclosed |
| WO-2017188357-A1 | SUBSTITUTED DIHYDROPYRROLOPYRAZOLE COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR DOSING IN COMBINATION WITH OTHER PSORIASIS TREATMENT DRUG | 宇部興産株式会社 | 2017-11-02 | — | — | WO | disclosed |
| EP-3214086-A1 | SUBSTITUTED DIHYDROPYRROLOPYRAZOLE COMPOUND | Ube Industries, Ltd. (JP) | 2017-09-06 | — | — | EP | disclosed |
| EP-3214086-A1 | SUBSTITUTED DIHYDROPYRROLOPYRAZOLE COMPOUND | Ube Industries, Ltd. (JP) | 2017-09-06 | — | — | EP | disclosed |
| EP-3194374-A1 | TRIAZOLE COMPOUNDS AS T-TYPE CALCIUM CHANNEL BLOCKERS | Idorsia Pharmaceuticals Ltd (CH) | 2017-07-26 | — | — | EP | disclosed |
| WO-2016068287-A1 | SUBSTITUTED DIHYDROPYRROLOPYRAZOLE COMPOUND | 宇部興産株式会社 | 2016-05-06 | — | — | WO | disclosed |
| WO-2016041892-A1 | TRIAZOLE COMPOUNDS AS T-TYPE CALCIUM CHANNEL BLOCKERS | ACTELION PHARMACEUTICALS LTD (CH) | 2016-03-24 | — | — | WO | disclosed |
| US-9221773-B2 | Benzamide derivatives | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2015-12-29 | — | — | US | disclosed |
| US-20130045982-A1 | BENZAMIDE DERIVATIVES | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2013-02-21 | — | — | US | disclosed |
| WO-2011079036-A1 | BENZAMIDE DERIVATIVES | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2011-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170313727-A1 | SUBSTITUTED DIHYDROPYRROLOPYRAZOLE COMPOUND | QDPR, CYP2D6, DCLK3 | HPGD 2108/4885CYP2C19 152/4885TSHR 2798/4885 |
| US-10246426-B2 | Triazole compounds as T-type calcium channel blockers | CACNA1I, CACNA1E, CACNA1G | HPGD 2322/4885CYP2C19 533/4885TSHR 483/4885 |
| US-10131679-B2 | Substituted dihydropyrrolopyrazole compound | QDPR, CYP2D6, DCLK3 | HPGD 2108/4885CYP2C19 152/4885TSHR 2798/4885 |
| US-20130045982-A1 | BENZAMIDE DERIVATIVES | BAD, BAK1, BRDT | HPGD 917/4885CYP2C19 3590/4885TSHR 3185/4885 |
| US-10968238-B2 | Substituted dihydropyrrolopyrazole compound | QDPR, CYP2D6, KCNJ11 | HPGD 1706/4885CYP2C19 158/4885TSHR 2880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.